Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SOD1 | P00441 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326740 | 0.80 | NSD2 (0.37) | KDM4EPOLBALDH1A1 | |
| SCHEMBL6328326 | 0.76 | SLC6A2 (0.39) | — | |
| SCHEMBL414388 | 0.72 | KMT2A (0.35) | POLBALDH1A1 | |
| SCHEMBL14505730 | 0.69 | KDM4E (0.40) | KDM4EPOLBALDH1A1 | |
| SCHEMBL15171472 | 0.66 | NFE2L2 (0.42) | CYP2C19 | |
| SCHEMBL14505731 | 0.64 | ALDH1A1 (0.51) | POLBALDH1A1 | |
| SCHEMBL14505732 | 0.64 | KMT2A (0.50) | POLBALDH1A1 | |
| SCHEMBL14505734 | 0.64 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL6153909 | 0.62 | CCKBR (0.59) | CYP2C19ALDH1A1 | |
| SCHEMBL14505735 | 0.61 | ALDH1A1 (0.33) | POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059831-A1 | Preparation of substituted butenolides via palladium-free etherification and amination of masked mucohalic acids | BLAZECKA PETER GARTH (CA) | 2005-03-17 | — | — | US | claimed |
| WO-2005026141-A2 | PROCESS FOR PREPARATION OF SUBSTITUTED BUTENOLIDES VIA PALLADIUM-FREE ETHERIFICATION AND AMINATION OF MASKED MUCOHALIC ACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050059831-A1 | Preparation of substituted butenolides via palladium-free etherification and amination of masked mucohalic acids | BLAZECKA PETER GARTH (CA) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059831-A1 | Preparation of substituted butenolides via palladium-free etherification and amination of masked mucohalic acids | DBH, OR51E2, OR10J3 | CYP2C19 65/4885KDM4E 1860/4885SOD1 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.